Exl01 in Cancer Immunotherapy

What is Exl01?
EXL01 is a novel drug candidate containing an unmodified single-strain of Faecalibacterium prausnitzii; a commensal bacterium being developed by Exeliom Biosciences as an oral therapy for a series of cancer indications to boost existing cancer treatments (anti-PD1/PD-L1 combination treatment).

The EXL01-strain is manufactured using a GMP compliant proprietary culture medium, under strict anaerobic conditions.
The EXL01-drug substance is formulated in gastro-resistant capsules for oral administration, designed to enable targeted delivery in the intestines.

Learn more about F. praustnizii in Immuno-Oncology
Learn more abouT Exl01


Exl01 in Immuno-Oncology



Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.